Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 614 | 583 | 369 | 307 | 229 | 214 | 176 | 183 |
| Operating profit | $m | -13.9 | -24.6 | ||||||
| Net profit | $m | -18 | 8 | -106 | -59 | -82 | -39 | -19 | -23 |
| EPS reported | $ | -1.80 | -1.05 | ||||||
| Operating cashflow per share | $ | 0.33 | 3.42 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.33 | 3.42 | ||||||
| Free cash flow | $m | 6.7 | 71.2 | ||||||
| Net debt | $m | -297 | -323 | ||||||
| Book value equity | $m | 459 | 444 | ||||||
| Book value per share | $ | 22.13 | 21.34 | ||||||
| Number of shares | m | 20.75 | 20.82 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.63 | 0.54 | ||||||
| P/S LTM | x | 1.36 | 1.38 | ||||||
| P/FCF LTM | x | 42.95 | 3.40 | ||||||
| EV/EBITDA LTM | x | -5.06 | 4.54 | ||||||
| EV/Sales LTM | x | 0.78 | -0.46 | ||||||
| Earnings Yield LTM | % | -13.39% | -7.82% | ||||||
| FCF Yield | % | 2.33% | 29.38% | ||||||
| Quality | |||||||||
| ROE | % | -8.45% | -4.26% | ||||||
| ROIC | % | -2.93% | -5.33% | ||||||
| Operating margin | % | -6.53% | -13.97% | ||||||
| Gross margin | % | 56.57% | 40.54% | ||||||
| FCF/Sales | % | 3.16% | 40.42% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -6.55% | -22.36% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.55 | 9.35 | ||||||
| Net Debt/EBITDA | x | 3.72 | 8.32 | ||||||
| EBIT/Net interest | x | -1,991.57 | - | ||||||
| Net debt/market cap | % | -102.43% | -133.52% | ||||||
| Net debt/Equity | x | -0.65 | -0.73 | ||||||
| Gross debt/equity | x | 0.03 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free